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Abstract  
ADAMTS13 is a metalloprotease that regulates von Willebrand factor (VWF) function. ADAMTS13-
mediated proteolysis is determined by conformational changes in VWF but may also depend upon 
its own conformational activation. Kinetic analysis of WT ADAMTS13 revealed ~2.5 fold reduced 
activity when compared to ADAMTS13 lacking its C-terminal tail (MDTCS) or its CUB1-2 domains 
(WT∆CUB1-2), suggesting that the CUB domains naturally limit ADAMTS13 function. Consistent with 
this, WT ADAMTS13 activity was enhanced ~2.5-fold by preincubation with either an anti-CUB mAb 
(20E9), or with VWF D4CK (the natural binding partner for the CUB domains). Furthermore, the 
isolated CUB1-2 domains not only bound MDTCS, but also inhibited activity up to 2.5-fold. 
Interestingly, a Gain of Function (GoF) ADAMTS13 spacer domain variant 
(R568K/F592Y/R660K/Y661F/Y665F) was ~2.5-fold more active than WT ADAMTS13, but could not 
be further activated by 20E9 mAb or VWF D4CK, and was unable to bind or be inhibited by the CUB1-
2 domains, suggesting that the inhibitory effects of the CUB domains involve an interaction with the 
spacer domain that is disrupted in GoF ADAMTS13. Electron microscopy demonstrated a “closed” 
conformation of WT ADAMTS13, and suggested a more “open” conformation for GoF ADAMTS13. 
The cryptic spacer domain epitope that is revealed by conformational unfolding also represents the 
core antigenic target for auto antibodies in TTP. We propose that ADAMTS13 circulates in a “closed” 
conformation, which is maintained by a CUB-spacer domain binding interaction. ADAMTS13 
becomes conformationally activated upon demand through interaction of its C-terminal CUB 
domains with VWF, making it susceptible to immune recognition. 
 
Significance statement 
We show a CUB-spacer domain interaction impedes the exposure of the ADAMTS13 spacer 
functional exosite. This prevents ADAMTS13 from interacting effectively with its complementary 
binding site in the VWF A2 domain. This CUB-spacer interaction is disrupted by interaction with the 
C-terminal domains of VWF, leading to conformational activation of ADAMTS13. This study also 
suggests that activation of ADAMTS13 reveals a cryptic epitope in the spacer domain that 
constitutes the auto antigenic core in patients with acquired TTP. These antibodies inhibit 
ADAMTS13, causing deposition of VWF and platelet rich microthrombi in small blood vessels, 
resulting in organ damage. This study therefore offers an insight into the complexity of both normal 
haemostatic control and the pathogenesis of auto immunity. 
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Introduction 
Von Willebrand factor (VWF) is a large, multidomain glycoprotein that is able to recognise vascular 
damage by binding to exposed collagen through its A3 domain (1-3). VWF tethered to collagen 
responds to shear forces by adapting its conformation (4). Under conditions of low shear, it is 
thought to adopt a globular conformation. At high shear, it unfolds and reveals its binding site for 
the platelet GpIbα receptor on its A1 domain, thereby facilitating platelet recruitment to the site of 
vascular injury.  A decisive factor in the ability of VWF to capture platelets is its unfolding in response 
to shear (5). 
VWF is heterogeneous with respect to its molecular size due to the varying degrees of 
multimerisation that occur within the endothelial cell. It is stored, prior to release into the plasma, 
as multimers that can be as large as 20-40-mers (6-9). Upon release from the cell, it is the highest 
molecular weight multimers which are haemostatically most active. Indeed, “ultra large” multimers 
present a potential hazard if their function is unregulated, as they can predispose to the formation 
of VWF-platelet microthrombi that can occlude small blood vessels, resulting in thrombotic 
thrombocytopenic purpura (TTP) (10). 
The metalloprotease ADAMTS13 is able to cleave the VWF A2 domain and, in doing so, dramatically 
reduces the multimeric size of VWF and its propensity to form platelet containing microthrombi (11, 
12). Cleavage of VWF by ADAMTS13 is a multistep process. An initial interaction takes place between 
the D4CK domains of globular VWF and ADAMTS13, which may serve to position protease in 
readiness for the VWF to unfold (13, 14). As unfolding occurs, exposure of the scissile bond, Y1605-
M1606, of the A2 domain is controlled by structural elements contained within this domain (15-18). 
Progressive unfolding allows distinct functional exosites within its A2 domain to be exposed and 
engaged by complementary binding sites on the protease, spacer and disintegrin-like domains (19-
23). Ultimately, docking of VWF scissile bond P1’, P1 and P3 residues into sub-sites on the protease, 
position the scissile bond for cleavage (24). Conformational changes in VWF are therefore essential 
for its efficient cleavage by ADAMTS13. 
In order to explore the possible role of conformation in ADAMTS13 function (25, 26), we have 
studied a recently described gain of function variant of ADAMTS13 (27). Jian et al. concluded that an 
ADAMTS13 variant comprising composite spacer domain substitutions 
R568K/F592Y/R660K/Y661F/Y665F (in what follows to be designated “GoF”) had ~4-fold increased 
ability to cleave VWF substrates (27). A similar increase in activity has also been observed previously 
by others upon removal of the C-terminal domains from ADAMTS13 (28). Based upon our 
investigation of the properties of ADAMTS13, the GoF variant and their derivatives, reported herein, 
we propose that ADAMTS13 adopts a globular conformation determined by interaction of its spacer 
and CUB domains.  
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Results 
Increased substrate recognition leads to hyperactivity in GoF ADAMTS13 
We have conducted a kinetic analysis of VWF115 cleavage and propose that there is a ~2 fold 
difference between WT ADAMTS13 and the GoF variant (27) (Figure 1A and kcat/Km values in Table 1). 
There was, however, no difference in kcat and the enhanced activity is instead due to an increased 
affinity for the substrate, as demonstrated by the Km values of 1.54 µM and 0.86 µM for WT and GoF 
ADAMTS13, respectively (p < 0.05). The KD(APP) values determined by equilibrium plate binding assays 
suggested a 2-fold increased affinity of GoF ADAMTS13 for VWF (Figure 1B).  This was confirmed by 
both steady state and global fit SPR analysis (Figure 1C, 1D and 1E) and was shown to be caused by 
an increased rate of association (Table 1, p < 0.001).  
Disruption of C-terminal interactions activates WT ADAMTS13 
The first step in VWF recognition by ADAMTS13 is mediated by binding of the VWF D4CK domains of 
globular VWF to the C-terminal domains of ADAMTS13 (13, 14). We hypothesised that this initial 
binding causes a conformational activation of ADAMTS13 that may be unnecessary in the GoF 
variant.  Addition of the VWF D4CK domain fragment to WT ADAMTS13 in a FRETS-VWF73 assay 
increased its activity (normalised against that of WT ADAMTS13) in a dose dependent manner, 
resulting in a 2-2.5 fold increase (Figure 2A and 2C, p < 0.001). This hyperactivity was similar to that 
exhibited by GoF ADAMTS13. Furthermore the activity of GoF ADAMTS13 was not then enhanced by 
VWF D4CK addition (Figure 2B and 2C).  
The 20E9 mAb recognises the CUB2 domain of ADAMTS13. Enhanced activity was observed upon 
addition of the 20E9 mAb to WT ADAMTS13 (Figure 2D and 2F, p < 0.001), reaching a maximal 
enhanced activity of 2.5 fold. GoF ADAMTS13 was unaffected by the antibody (Figure 2E and 2F), 
suggesting that the CUB domains may play an important role in ADAMTS13 activation.   
Regulation of ADAMTS13 activity by the CUB domains 
We hypothesised that the C-terminal CUB domains interact with the spacer domain in the native WT 
ADAMTS13. We predicted that removal of the C-terminal domains (in the truncated variant MDTCS) 
would produce a similar activity enhancement to that observed with VWF D4CK and with 20E9 mAb. 
Indeed, both WT and GoF MDTCS variants are fully hyperactive with activity profiles 
indistinguishable from GoF ADAMTS13 (Figure 3A, 3B and 3C).  
Moreover, truncation of ADAMTS13 after the TSP2-8 domains (WT∆CUB1-2 variant) produced an 
enhancement similar to that observed in WT MDTCS (Figure 3D and 3F). Furthermore, 
reintroduction of the isolated CUB1-2 domain fragment had a dose-dependent inhibitory effect on 
both WT MDTCS and WT∆CUB1-2, reducing activity similar to that of WT ADAMTS13 (Figure 3A and 
3D). In contrast, C-terminal truncation of GoF ADAMTS13 had no influence on its activity and 
addition of the CUB1-2 domain fragment was ineffective even at high concentrations (Figures 3B and 
3E). 
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A CUB-spacer domain binding interaction  
We developed a reciprocal co-immunoprecipitation (co-IP) experiment to directly analyse any CUB-
spacer domain interaction. WT MDTCS and the CUB1-2 domain fragment bound in solution and 
remained in complex when either fragment was pulled down specifically by mAb. This resulted in 
both fragments being detected in immunoprecipitation (IP) eluates and depleted from solution 
(Figure 4A). In contrast, when GoF MDTCS and CUB1-2 were incubated, only the fragment being 
pulled down by its corresponding mAb was detected in the eluate, with the other fragment 
remaining in solution. As GoF MDTCS differs from WT MDTCS only by its spacer domain 
substitutions, this strongly suggested that the spacer domain is the site of CUB domain binding to 
MDTCS. 
We further refined this approach to allow the quantification of binding and elution of MDTCS from 
CUB1-2 immobilised on magnetic beads (see ‘Experimental Procedures’). This allowed us to perform 
MDTCS-CUB co-IP over a range of MDTCS concentrations and to accurately quantify bound and free 
MDTCS. A KD(APP) value of ~40 nM was determined for the binding of CUB1-2 and WT MDTCS (Figure 
4B). In agreement with earlier co-IP experiments, minimal binding was observed between CUB1-2 
and GoF MDTCS.  
ADAMTS13 can exist in a ‘closed’ or more ‘open’ conformation 
Binding of the CUB domains to the spacer domain in WT ADAMTS13 would require flexibility in the 
C-terminal domains. We hypothesised that this would result in an observable change in the overall 
conformation of the full length protein and we observed this using TEM of negatively stained 
proteins (Figure 5). Analysis of the WT ADAMTS13 sample produced a variety of different 
monodisperse orientational particles measuring between 12-16nm, consistent with a protein ~170 
kDa in size. The main projection view had a clear compact, globular conformation with an additional 
side ‘bulge’ of projection density (Figure 5A – panel 3); we have assigned this as the ‘closed’ 
ADAMTS13 conformation, which corresponds to the native ADAMTS13. Examination of a similar 
number of  GoF ADAMTS13 particles, revealed similar sized particles, but the projection averages 
produced were somewhat more linear (Figure 5B – panel 3) and the projection view with the side 
‘bulge’ was absent. The projections were also not as sharply delineated as the ADAMTS13 samples 
and this combined with a different population of particle projections suggests that the complex has 
adopted a more open organisation with some local region of protein in a flexible/unstructured 
conformation  (Figure 5 – end panel). These results are compatible with exposure of spacer domain 
VWF binding exosites and hyperactivity.  
WT ADAMTS13 conformational activation reveals its cryptic TTP auto antibody binding epitopes  
WT ADAMTS13 was inhibited by TTP patient auto antibodies and the single TTP patient derived II-1 
mAb (29) in FRETS-VWF73 assays (Figure 6A). However, despite there being a large excess of these 
antibodies added to activity assays, ADAMTS13 was only inhibited by 60%, compared to 95% 
inhibition of MDTCS by the same TTP aAb (Figure 6C). This suggests that WT ADAMTS13, in its 
‘closed’ and relatively inactive state, might not be readily recognised by these antibodies. This was 
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confirmed by IP of WT ADAMTS13 by the II-1 mAb covalently linked to magnetic beads. When 
converted to its ‘open’ conformation using the activating 20E9 mAb (Figure 6D), or VWF D4CK 
fragment (Figure 6E), recognition of WT ADAMTS13 was dramatically increased. The spacer domain 
mutations in GoF ADAMTS13 have been shown previously to abolish this antigenicity (see also Figure 
6B); this was confirmed in this study in both FRET and IP assays (Figure 6D and Figure 6E). 
 
Discussion 
The concept of conformational activation of ADAMTS13 has been alluded to previously as a possible 
explanation for suggested conflicting roles of the CUB domains (25, 30). We present here results 
which indicate that ADAMTS13 naturally adopts a folded or closed conformation, with folding 
mediated through an interaction between the C-terminal CUB domains and the more central spacer 
domain. The importance of this folding is suggested by the known functional importance of the 
spacer domain, which serves as a critical exosite that interacts with a cryptic binding site revealed on 
the VWF A2 domain as it unfolds (31). This provides an essential localising mechanism that helps 
position the ADAMTS13 protease domain within reach of the VWF scissile bond. A consequence of 
the folded conformation of ADAMTS13 is that the important spacer domain exosite is only partially 
available and requires full exposure to enable proteolysis of VWF to proceed efficiently. It is now 
established that ADAMTS13 can interact with globular VWF through recognition of its surface 
exposed C-terminal domains, D4CK, by the TSP-CUB domain region of ADAMTS13 (13, 14). This 
binding interaction has been regarded as a positioning one, enabling a small amount of ADAMTS13 
to associate reversibly with VWF in its globular conformation, pending VWF unfolding (14). However, 
we now present evidence that the VWF D4CK fragment can increase the activity of ADAMTS13 in a 
FRETS-VWF73 assay. We suggest, therefore, that on binding to the VWF D4CK domains, ADAMTS13 
unfolds, to fully expose its cryptic spacer domain exosite. Once unfolded, the spacer domain can 
directly contact its VWF A2 complementary interaction site and enhance the cleavage process. The 
precise mechanism for VWF D4CK activation requires further investigation, but it is plausible to 
suggest that its binding to the region around or including the CUB domains disrupts the spacer-CUB 
binding interaction, causing unfolding and activation. 
An interaction between the spacer and CUB domains of ADAMTS13 is supported by the results of 
addition of activating mAb, as well as activity and binding assays of C-terminal truncated WT 
ADAMTS13 in the presence of isolated CUB fragments. Concerning the activating mAb, we have 
shown that 20E9 mAb, an antibody that recognises the CUB2 domain region of ADAMTS13, can 
increase the activity of WT ADAMTS13. In FRETS-VWF73 assays, isolated CUB fragments inhibit the 
proteolytic activities of both WT MDTCS and WT∆CUB1-2 truncation variants. Furthermore, in 
solution binding pull down experiments, we have shown that CUB fragments can directly bind to 
these derivatives, with an estimated affinity of ~40 nM. Although these experiments necessarily 
used free CUB domain fragments, which might not interact with the spacer domain in exactly the 
same way or with the same affinity when contiguous with their neighbouring TSP domains, they do 
provide compelling evidence of a moderate affinity binding interaction between spacer and CUB 
domains. Furthermore, the isolated CUB domain fragments inhibited WT∆CUB1-2, which retains its 
TSP domains, suggesting that the CUB binding site on the spacer domain was not introduced by 
complete deletion of these C-terminal domains. 
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Additional evidence for conformational activation of ADAMTS13 comes from our characterisation of 
GoF ADAMTS13. This variant is shown to have an enhanced association rate with VWF fragments 
leading to ~2-2.5 fold overall enhanced cleavage of the scissile bond. The properties of this variant 
might arise in part because of an increased molecular recognition of its substrate induced by the 5 
introduced substitution mutations in the spacer domain. Alternatively, the enhanced activities could 
also arise by disruption of the spacer-CUB domain interaction in this variant by the introduced 
spacer domain substitution mutations. We propose that this variant adopts a native unfolded 
conformation and is therefore essentially preactivated. Support for this idea is provided by its 
enhanced association rate with VWF115 and by failure of 20E9 activating antibodies to enhance 
activity of the variant. It is again interesting that pull down experiments with GoF MDTCS could not 
show it binding the isolated CUB1-2 domain fragment. Moreover, the lack of inhibition in FRETS-
VWF73 assay by the CUB domain fragment of GoF MDTCS and GoF∆CUB1-2 truncation variants 
provides further support for lack of a masking interaction by the CUB domains and therefore a 
preactivation state. From our TEM experiments we have visualised WT ADAMTS13 as a globular 
molecule while GoF ADAMTS13 appears to be less compact. 
A potential advantage of conformational activation of ADAMTS13 is that localisation of the activated 
form of the protease will occur on the surface of its substrate, VWF. It is conceivable that this might 
offer a protective mechanism, particularly as it has been demonstrated that ADAMTS13 is 
susceptible to cleavage by several coagulation proteases (32, 33). But conformational activation can 
also have untoward consequences. It has been recognised that auto antibodies against ADAMTS13 
cause or predispose to acquired TTP (34). The trigger factors that initiate the auto immune response 
have yet to be fully delineated. It is interesting that the majority of patients with TTP have auto 
antibodies that are directed to the ADAMTS13 spacer domain (20, 35, 36). We propose that this is 
because this domain is naturally cryptic, shielded by the CUB domains. During the process of 
ADAMTS13 activation the cryptic epitope(s) are revealed and might be recognised as foreign during 
a concurrent immune activation. Support for this concept is provided by the increased recognition of 
WT ADAMTS13 spacer domain by the patient derived II-1 mAb when the activating 20E9 antibody or 
VWF D4CK fragment is present. Consequently, our results on the conformational activation of 
ADAMTS13 provide insight to both the proteolytic process by which ADAMTS13 recognises VWF and 
to the mechanism of auto antibody formation in TTP. 
 
Experimental Procedures 
Production of recombinant ADAMTS13 and VWF fragments  
Recombinant human ADAMTS13 with a C-terminal Myc/His6 tag in pCDNA3.1 (32) was used to 
generate GoF ADAMTS13 (R568K/F592Y/R660K/Y661F/Y665F) by sequential site directed 
mutagenesis. The same mutagenesis primers were also used to introduce the GoF mutations into 
WT MDTCS-Myc/ His6.  The truncated variants WT∆CUB1-2 and GoF∆CUB1-2 and the CUB1-2 domain 
fragment were generated by inverse PCR using the full length ADAMTS13 constructs.  All ADAMTS13 
variants and fragments were expressed in HEK293S cells, purified and quantified  using in house 
ELISAs as described previously (37). For electron microscopy, ADAMTS13 was purified to 
homogeneity by gel filtration using a Superose 12 10/300 GL column (GE Healthcare). 
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The VWF A2 domain fragment VWF115 (VWF residues 1554-1668) was expressed and purified as 
previously described (32). The VWF D4CK domain fragment (VWF residues 1874-2813) in the vector 
pcDNA 3.1/His was transiently expressed in HEK293S, purified by FPLC and quantified by ELISA (13). 
 
Production and characterization of anti-ADAMTS13 mAb 20E9 
The 20E9 mAb was one of 30 anti-ADAMTS13 mAbs obtained after immunisation of WT Balb/c mice 
with recombinant WT ADAMTS13, followed by fusion of their spleen cells with Sp2/0 myeloma cells. 
The epitope of mAb 20E9 is situated in the CUB2 domain as determined through epitope mapping 
using a series of ADAMTS13 variants where all domains were individually deleted.  
 
TTP patient IgG preparation 
 
Total IgG was isolated from the presentation plasma sample of a TTP patient with high titre anti-
ADAMTS13 IgG directed against the spacer domain, using melon gel spin columns (Thermo 
Scientific). Ethical approval for the use of the sample was previously obtained from the local 
Research Ethics Committee (reference:08/H0716/72). 
 
ADAMTS13 activity assays  
Recombinant VWF A2 domain fragments VWF115 (VWF residues 1554-1668) and FRETS-VWF73 
(VWF residues 1596-1668) which span the ADAMTS13 cleavage site and spacer domain binding 
exosites, were used as proteolytic substrates to determine the activity of ADAMTS13 and its 
variants. Cleavage of VWF115 by ADAMTS13 was carried out as described (19). For FRETS-VWF73 
assays ADAMTS13, MDTCS and ∆CUB1-2 variants (WT and GoF) were diluted to 0.3 nM in reaction 
buffer (5 mM Bis-Tris, pH 6.0/25 mM CaCl2/0.005% Tween-20) in white 96-well plates (Nunc).  
Purified CUB1-2 domain fragment, VWF D4CK, 20E9 mAb, II-1 mAb or TTP patient IgG were added 
before being pre-incubated for 45 min at 37 °C. The reaction was initiated by the addition of an 
equal volume of 4 µM FRETS-VWF73 substrate (Peptanova GMBH). Fluorescence (excitation 340 nm; 
emission 460 nm) was measured at 30°C at 1 minute intervals for 1 hour using a Fluostar Omega 
plate reader (BMG Labtech). Results were normalised to WT ADAMTS13 activity to allow cross 
comparison of any changes.  
 
Equilibrium plate binding assay and surface plasmon resonance  
Binding of VWF115 to ADAMTS13 was determined by equilibrium plate binding assay (13, 19), and by surface 
plasmon resonance using a BIAcore T100 system (BIAcore) as described (13).  
 
   
Co-immunoprecipitation analysis of CUB and MDTCS interaction 
Samples containing 40 nM MDTCS (WT or GoF), in the absence/presence of 40 nM CUB1-2 fragment, 
were immunoprecipitated using Protein G Dynabeads (Invitrogen) coupled to either the 3H9 mAb 
against the ADAMTS13 metalloprotease domain (33, 38), the 20E9 mAb directed against the 
ADAMTS13 CUB domains or the IgG isotype control 15D7 mAb (39). Beads were washed, and bound 
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protein eluted in 1x LDS loading buffer at 70 °C for 10 min. Inputs (pre-IP), flow through (post-IP) and 
bound protein in eluates were analysed by SDS PAGE and anti-ADAMTS13 western blot.  
For CUB-MDTCS affinity determination, blocked and 20E9 mAb coated Dynabeads were pre-
incubated with 100 nM CUB1-2 domain fragment and used to immunoprecipitate MDTCS (WT or 
GoF) at increasing concentrations (5-200 nM). Bound MDTCS was eluted in 20 mM Tris, pH 7.4/1 M 
NaCl. Bound and free MDTCS concentrations were determined by in house ELISA and KD values were 
determined by fitting data to a one site binding hyperbola using Prism 4 software (Graphpad). 
 
TTP auto antibody binding 
The TTP patient derived II-1 mAb (29) (kindly provided by Prof J. Voorberg and Dr N. Sorvillo) was 
covalently coupled to M280 tosylactivated Dynabeads (Invitrogen) following manufacturer’s 
instructions. The coupled beads were added to 40 nM ADAMTS13 (WT or GoF) and pre-incubated for 
1 hour at 37 °C in the absence/presence of 4 µg 20E9 mAb. After 4 hours incubation, the beads were 
washed and bound protein eluted in LDS loading buffer. Inputs (pre-IP), flow through (post-IP) and 
eluates were analysed by SDS PAGE and anti-ADAMTS13 western blot. 
 
Transmission electron microscopy 
Fully purified samples of ADAMTS13 variants (10 µl of ∼10 µg/ml) in 20 mM Tris pH 7.8/150 mM 
NaCl/5 mM CaCl2 were applied to glow-discharged continuous carbon-coated 400-mesh copper grids 
(TAAB Laboratories) for 1 minute. Excess sample was blotted using Whatman paper and the protein 
was negatively stained by the addition of 10 µl 5 % (w/v) uranyl acetate for 1 minute. Images were 
acquired at a nominal magnification of 39,000x using a Philips Tecnai30 Polara FEG electron 
microscope operating at 200 kV low-dose mode and recorded on a Gatan 4K charge-coupled device 
camera. 
Image analysis of the recorded TEM DM3 data files was performed using EMAN2 
(http://blake.bcm.edu/emanwiki/EMAN2).  Equivalent datasets of ~6000 particles were boxed out of 
images using semi-automated swarm picking; any aggregated or overlapping data were discarded.  
Data were CTF corrected and the dataset underwent multi-statistical reference-free 2-D 
classification. Data were auto-masked, a maximum shift of 5 pixels was applied and cross correlation 
coefficient (CCC) was used as the main comparator. Projection averages of each particle orientations 
were selected and a low pass Gaussian filter (20 Angstroms) was applied. 
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Figure legends 
 
Figure 1. The increased VWF115 binding affinity and proteolytic activity of GoF ADAMTS13. A, 
ADAMTS13 variants were incubated with increasing concentrations of VWF115 and initial rates of 
substrate proteolysis were used to determine k
cat
 and K
m
 values (listed in Table 1). B, the increased 
substrate recognition suggested by the reduced K
m
 of the GoF ADAMTS13 variant was confirmed by 
equilibrium plate binding assay. A 2 fold reduction in K
D(APP)
 was confirmed by SPR using both steady 
state (C) and global fit analysis (D and E) . The results presented are representative of three 
independent experiments. 
Figure 2. WT ADAMTS13 activity can be enhanced by the addition of a VWF D4CK domain 
fragment or by the addition of an activating mAb targeting the CUB2 domain. A-C, the effect of the 
VWF D4CK domain fragment on ADAMTS13 activity was determined using the FRETS-VWF73 assay. 
WT and GoF ADAMTS13 were pre-incubated with varying concentrations of the VWF C-terminal 
fragment before initiation of the assay by the addition of FRETS-VWF73.  GoF ADAMTS13 activity 
was >2 fold higher than WT ADAMTS13 and was not further increased by VWF D4CK. D-F, the effect 
of the activating mAb was assessed in the same manner. The antibody elicited a >2-fold increase in 
activity of the WT but had no effect on the already hyperactive GoF variant. Results are presented as 
mean ± S.E.M. (n=3). 
 
Figure 3. WT ADAMTS13 hyperactivity resulting from C-terminal truncation can be inhibited by the 
CUB1-2 domains. A-C, the activity of WT and GoF MDTCS variants were determined by FRETS-
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VWF73 assay. Both enzymes exhibit hyperactivity when compared to WT ADAMTS13. WT MDTCS 
activity can be inhibited by the addition of CUB1-2 domain fragment, however the fragment has no 
significant effect on GoF MDTCS. D-F, specific removal of the CUB-domains from both WT and GoF 
ADAMTS13 also results in a >2 fold increase in activity. The CUB1-2 domain fragment displays an 
inhibitory activity when added to WT∆CUB1-2, albeit at higher concentrations than are required for 
WT MDTCS inhibition. Results are presented as mean ± S.E.M. (n=3). 
 
Figure 4. The CUB1-2 domain fragment binds to WT MDTCS through the spacer domain. A, MDTCS 
(filled arrowhead) and CUB1-2 (present also as a partially cleaved, faster mobility fragment) (open 
arrowheads) were immunoprecipitated using Protein G beads coupled to the indicated mAb (3H9, 
directed to the protease domain, or 20E9, directed to the CUB2 domain). The MDTCS and CUB 
fragments present in solution pre/post IP, and bound proteins after elution, were detected by 
polyclonal anti-ADAMTS13 western blot. Co-IP of WT MDTCS with CUB1-2 is evident under both 
experimental conditions but binding of GoF MDTCS was not apparent. MDTCS and CUB1-2 were also 
incubated with an isotype control IgG (15D7 mAb). B, Affinity between the CUB and spacer domains 
was determined with WT and GoF MDTCS at a range of concentrations (5-200 nM) and IP using 
magnetic beads coated with 20E9 mAb complexed to the CUB1-2 domain fragment. Bound and free 
MDTCS were determined by ELISA and used to derive a K
D 
of 41.6 ± 3.4 nM for WT MDTCS.  
Figure 5. The proposed alteration of WT ADAMTS13 conformation upon activation. TEM analysis of 
WT ADAMTS13 (A) and GoF ADAMTS13 (B). The figure shows representative examples of negatively 
stained TEM fields of view, individual particles selected for analysis and the results of multi-statistical 
reference-free class averaging. Scale bars are all 50nm. The last panel shows a schematic 
representation of WT ADAMTS13 conformation. This is compatible with the existence of an 
interaction between the CUB domains (C1 and C2) and spacer domain (S), shielding the VWF A2 
domain binding exosites. We propose that activation results in a more linear and flexible ‘open’ 
ADAMTS13 conformation which would expose cryptic spacer domain exosites allowing engagement 
of the unfolded VWF A2 domain. 
 
Figure 6. WT ADAMTS13 recognition and inhibition by TTP auto antibodies is enhanced upon 
activation by the anti-CUB 20E9 mAb but is abolished in the GoF variant. A, proteolysis of the 
FRETS-VWF73 substrate by WT ADAMTS13 is markedly decreased when the enzyme is pre-incubated 
with either TTP patient total IgG or TTP patient derived II-1 mAb. B, GoF ADAMTS13 activity in 
FRETS-VWF73 assays is increased 2-fold compared to WT ADAMTS13 (see panel C), however it is not 
impaired by either antibody. Immunoprecipitation of ADAMTS13 in solution using the II-1 mAb 
covalently coupled to magnetic beads suggests that WT ADAMTS13 is not efficiently recognised. Pre-
treatment of WT ADAMTS13 with the activating anti-CUB 20E9 mAb (D) or the VWF D4CK domain 
fragment (E) greatly increases its capture by the beads. 
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Figure 1 
 
 
Table 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P l a t e  B i ndi ng SPR  R U ma x
k c a t K m k c a t  /  K m
k c a t  /  K m      
( T i me  c o u r s e )
K D ( A P P ) k a k d K D K D
( s - 1 ) ( µ M ) ( 10 5  M - 1  s - 1 ) ( 10 5  M - 1  s - 1 ) ( nM ) ( 10 4  M - 1  s - 1 ) ( 10 - 3  s - 1 ) ( nM ) ( nM )
WT A DA M TS 13 0.71 ± 0.09 1.54 ± 0.20 4.1 ± 0.5 5.5 ± 0.7 26.4 ± 3.0 3.72 ± 0.16 2.58 ± 0.01 72.3 ± 1.3 69.8 ± 6.2
GoF A DA M TS 13 0.62 ± 0.02 0.86 ± 0.07 8.3 ± 0.7 10.4 ± 0.3 11.5 ± 1.4 6.82 ± 0.19 2.64 ± 0.01 38.5 ± 1.2 35.8 ± 2.6
The act ivit ies of  ADAMTS13 variant s were det ermined by kinet ic analysis of  t he init ial rat es of  VWF115 prot eolysis. The binding int eract ions bet ween VWF115 and 
ADAMTS13 var iant s were det ermined by equilibr ium plat e binding assays (KD(A P P))  and SPR (ka, kd and KD)  Mean values ± SEM are based on 3 independent  experiment s.
V W F  Pro t eo lysis
Tab le 1.  The act ivit y and  V W F 115 b ind ing  af f init y o f  A D A M TS13  variant s
V W F115 B ind ing
SPR  Glob al F it t ing
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